Acupuncture for Chronic Pelvic Pain

April 9, 2026 updated by: David Moss

The objective of this study is to determine if alternative pain management strategies, namely acupuncture, may help reduce intensity of female pelvic pain compared to other pain control modalities. This research study will focus specifically on the Dragon's protocol of acupuncture which will seek to alleviate chronic non-endometriosis pelvic pain for women both with and without a history of sexual assault.

This study may support evidence for an inexpensive alternative means of treatment for patients with or without traumatic sexual history and chronic pelvic pain.

Study Overview

Status

Recruiting

Detailed Description

The objective of this study is to determine if alternative pain management strategies, namely acupuncture, may help reduce intensity of female pelvic pain compared to other pain control modalities. This research study will focus specifically on the Dragon's protocol of acupuncture which will seek to alleviate chronic non-endometriosis pelvic pain for women both with and without a history of sexual assault. The Dragons protocol consists of two parts, both completed at the same visit; external Dragons (needles are placed on the dorsal surface of the body) and internal Dragons (needles are placed on the ventral surface of the body). In Chinese Acupuncture theory, external dragons represent the traumatic events that happen in our life and the internal dragons represent dragons that live in the body and fight off the external dragons. It is used to treat post-traumatic stress. During external dragons the patient thinks about prior trauma (let the external dragons in) then during the second phase of treatment the internal dragons fight off the external dragons. From a western neurobiology perspective, clinical experience suggests that patients with post-traumatic stress have memories stored in the limbic system, that when triggered, activate the sympathetic nervous system. Dragons allows the brain to "reprocess" these memories so that triggers do not activate a sympathetic response in the patient. The mechanism is unknown, but the investigators theorize it may be due to vagal stimulation from the needles while the patient "relives" the traumatic event, thus experiencing the event in a parasympathetic state. This intervention will be compared to other treatment modalities such as pelvic floor physical therapy, non-steroidal anti-inflammatories, Osteopathic Manipulative Medicine, or any other usual means to achieve pain control offered by their providers.

The investigators will measure pre-procedure and post-procedure pain levels using the standard military Defense and Veterans Pain Rating Scale (DVPRS) in addition to a literature-based pelvic pain questionnaire, the Female Genitourinary Pain Index (GUPI). In addition to the pain index scales, patients with a history of sexual trauma will receive the PTSD Checklist for DSM-5 (PCL-5) which is a standardized measurement tool for assessing for PTSD. The provided acupuncture intervention, Dragon's, is classically used to treat both physical and emotional pain. Therefore, a sub-analysis will be performed to evaluate improvement in PTSD symptoms in those with a history of sexual assault and trauma.

The hypothesis of this study is that acupuncture with Dragon's will reduce chronic pelvic pain in females with and without a history of sexual trauma as it is designed to treat both physical and emotional pain. This is a relatively safe, effective, and non-invasive treatment strategy that could be offered as an alternative means of pain control when traditional modalities are ineffective.

Screening visit (30 minutes)

  • Obtain and document signed Informed Consent document and HIPAA Authorization
  • Verify subject eligibility based on inclusion/exclusion criteria via medical record review
  • Record all medications the subject is taking
  • Collect demographic information to include DoD ID, age, race, gender, military status (active duty, reserve, retired, separated or dependent), history of sexual assault prior to onset of pelvic pain, history of mental health diagnoses (e.g. anxiety, depression, PTSD), prior treatments used to treat pelvic pain

Patient sample will be both control and treatment groups. Individuals will not be divided into distinct groups. Patients will serve as their own controls. Control patients will be participating in standard of care therapies including physical therapy, psychotherapy, behavioral health, typical primary care management, etc. as deemed appropriate by the primary care provider for 4 weeks prior to study intervention. The same patients will then be re-evaluated and will be offered Acupuncture with Dragon technique (see attachment Protocol for Needle Insertion) as a means of pain control once per week for 4 weeks. Pain outcomes will be assessed with Defense and Veterans Pain Rating Scale (DVPRS) and Female Genitourinary Pain Index (GUPI). For subjects with a history of sexual trauma, a sub analysis will assess symptom change before and after treatment with PTSD Checklist for DSM-5 (PCL-5).

Visit 1 (week 0) (may be same day as screening visit) (20 minutes):

  • Administer DVPRS including supplemental quality of life questions
  • Administer GUPI
  • Administer PCL-5 to subjects with a history of sexual assault

Visit 2 (week 4) (60 minutes) (In-Person):

  • Subjects will report which treatments they have received since the screening visit
  • Administer DVPRS including supplemental quality of life questions
  • Administer GUPI
  • Administer PCL-5 Monthly to subjects with a history of sexual assault
  • The Dragons Script will be read to the subjects by the provider administering treatment
  • Subjects will receive their initial Acupuncture treatment with Dragons

Visit 3 (week 5) (60 minutes) (In-Person):

  • Administer DVPRS including supplemental quality of life questions
  • Administer GUPI
  • Administer PCL-5 Weekly to subjects with a history of sexual assault
  • The Dragons Script will be read to the subjects by the provider administering treatment (visits 3-5 the subject can elect to read the script themselves).
  • Subjects will receive their second Acupuncture treatment with Dragons

Visit 4 (week 6) (60 minutes) (In-Person):

  • Administer DVPRS including supplemental quality of life questions
  • Administer GUPI
  • Administer PCL-5 Weekly to subjects with a history of sexual assault
  • The Dragons Script will be read to the subjects by the provider administering treatment (visits 3-5 the subject can elect to read the script themselves).
  • Subjects will receive their third Acupuncture treatment with Dragons

Visit 5 (week 7) (60 minutes) (In-Person):

  • Administer DVPRS including supplemental quality of life questions
  • Administer GUPI
  • Administer PCL-5 Weekly to subjects with a history of sexual assault
  • The Dragons Script will be read to the subjects by the provider administering treatment (visits 3-5 the subject can elect to read the script themselves).
  • Subjects will receive their fourth Acupuncture treatment with Dragons

Visit 6 (week 11) (60 minutes) May be done virtually:

  • Administer DVPRS including supplemental quality of life questions
  • Administer GUPI
  • Administer PCL-5 Monthly to subjects with a history of sexual assault

Study Type

Interventional

Enrollment (Estimated)

64

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Nevada
      • Nellis Air Force Base, Nevada, United States, 89191

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

**Patients must be able to get care at Nellis Air Force Base (a military installation) in order to participate in this study**

Inclusion Criteria:

  • Active Duty and DoD Female Beneficiaries (i.e. former military, spouse, dependent) aged 21-65 with chronic pelvic pain
  • Have negative laparoscopic findings for endometriosis

Exclusion Criteria:

  • Severe mental health disorders to include any disorder with psychotic features (e.g schizophrenia, bipolar, schizoaffective disorder)
  • Pelvic pain as a result of severe physical trauma (excluding sexual assault) such as traumatic childbirth, pelvic fractures or any other trauma as determined by the PI or AI.
  • Pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Patient Cohort: Control
Patient sample will be both control and treatment groups. Individuals will not be divided into distinct groups. Patients will serve as their own controls. Control patients will be participating in standard of care therapies including physical therapy, psychotherapy, behavioral health, typical primary care management, etc. as deemed appropriate by the primary care provider for 4 weeks prior to study intervention. The same patients will then crossover and be re-evaluated and will be offered Acupuncture with Dragon technique (see attachment Protocol for Needle Insertion) as a means of pain control once per week for 4 weeks.
Standard of care therapies including physical therapy, psychotherapy, behavioral health, typical primary care management, etc. as deemed appropriate by the primary care provider for 4 weeks prior to study intervention.
Experimental: Patient Cohort: Intervention
Patient sample will be both control and treatment groups. Individuals will not be divided into distinct groups. Patients will serve as their own controls. Control patients will be participating in standard of care therapies including physical therapy, psychotherapy, behavioral health, typical primary care management, etc. as deemed appropriate by the primary care provider for 4 weeks prior to study intervention. The same patients will then crossover and be re-evaluated and will be offered Acupuncture with Dragon technique (see attachment Protocol for Needle Insertion) as a means of pain control once per week for 4 weeks.
The Dragons Script will be read to the subjects by the provider administering treatment. Subjects will receive their Acupuncture treatment with Dragons protocol.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Defense and Veterans Pain Rating Scale (DVPRS)
Time Frame: Visit 1 (Week 0)
The DVPRS consists of an 11-point numerical rating scale with 0 indicating no pain and 10 indicating severe pain. It has been confirmed for reliability and validity in measuring both acute and chronic pain and is currently the standard for pain measurement throughout DoD and VA health systems. The DVPRS has demonstrated linear scale qualities allowing parametric methods to be used.
Visit 1 (Week 0)
Defense and Veterans Pain Rating Scale (DVPRS)
Time Frame: Visit 2 (Week 4)
The DVPRS consists of an 11-point numerical rating scale with 0 indicating no pain and 10 indicating severe pain. It has been confirmed for reliability and validity in measuring both acute and chronic pain and is currently the standard for pain measurement throughout DoD and VA health systems. The DVPRS has demonstrated linear scale qualities allowing parametric methods to be used.
Visit 2 (Week 4)
Defense and Veterans Pain Rating Scale (DVPRS)
Time Frame: Visit 3 (Week 5)
The DVPRS consists of an 11-point numerical rating scale with 0 indicating no pain and 10 indicating severe pain. It has been confirmed for reliability and validity in measuring both acute and chronic pain and is currently the standard for pain measurement throughout DoD and VA health systems. The DVPRS has demonstrated linear scale qualities allowing parametric methods to be used.
Visit 3 (Week 5)
Defense and Veterans Pain Rating Scale (DVPRS)
Time Frame: Visit 4 (Week 6)
The DVPRS consists of an 11-point numerical rating scale with 0 indicating no pain and 10 indicating severe pain. It has been confirmed for reliability and validity in measuring both acute and chronic pain and is currently the standard for pain measurement throughout DoD and VA health systems. The DVPRS has demonstrated linear scale qualities allowing parametric methods to be used.
Visit 4 (Week 6)
Defense and Veterans Pain Rating Scale (DVPRS)
Time Frame: Visit 5 (Week 7)
The DVPRS consists of an 11-point numerical rating scale with 0 indicating no pain and 10 indicating severe pain. It has been confirmed for reliability and validity in measuring both acute and chronic pain and is currently the standard for pain measurement throughout DoD and VA health systems. The DVPRS has demonstrated linear scale qualities allowing parametric methods to be used.
Visit 5 (Week 7)
Defense and Veterans Pain Rating Scale (DVPRS)
Time Frame: Visit 6 (Week 11)
The DVPRS consists of an 11-point numerical rating scale with 0 indicating no pain and 10 indicating severe pain. It has been confirmed for reliability and validity in measuring both acute and chronic pain and is currently the standard for pain measurement throughout DoD and VA health systems. The DVPRS has demonstrated linear scale qualities allowing parametric methods to be used.
Visit 6 (Week 11)
Female Genitourinary Pain Index (GUPI)
Time Frame: Visit 1 (Week 0)
GUPI is a validated instrument to assess the degree of symptoms in both men and women with genitourinary pain complaints. It has a range of 0 to 45 and has also demonstrated linear scale qualities allowing parametric methods to be used.
Visit 1 (Week 0)
Female Genitourinary Pain Index (GUPI)
Time Frame: Visit 2 (Week 4)
GUPI is a validated instrument to assess the degree of symptoms in both men and women with genitourinary pain complaints. It has a range of 0 to 45 and has also demonstrated linear scale qualities allowing parametric methods to be used.
Visit 2 (Week 4)
Female Genitourinary Pain Index (GUPI)
Time Frame: Visit 3 (Week 5)
GUPI is a validated instrument to assess the degree of symptoms in both men and women with genitourinary pain complaints. It has a range of 0 to 45 and has also demonstrated linear scale qualities allowing parametric methods to be used.
Visit 3 (Week 5)
Female Genitourinary Pain Index (GUPI)
Time Frame: Visit 4 (Week 6)
GUPI is a validated instrument to assess the degree of symptoms in both men and women with genitourinary pain complaints. It has a range of 0 to 45 and has also demonstrated linear scale qualities allowing parametric methods to be used.
Visit 4 (Week 6)
Female Genitourinary Pain Index (GUPI)
Time Frame: Visit 5 (Week 7)
GUPI is a validated instrument to assess the degree of symptoms in both men and women with genitourinary pain complaints. It has a range of 0 to 45 and has also demonstrated linear scale qualities allowing parametric methods to be used.
Visit 5 (Week 7)
Female Genitourinary Pain Index (GUPI)
Time Frame: Visit 6 (Week 11)
GUPI is a validated instrument to assess the degree of symptoms in both men and women with genitourinary pain complaints. It has a range of 0 to 45 and has also demonstrated linear scale qualities allowing parametric methods to be used.
Visit 6 (Week 11)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PTSD Checklist for DSM-5 (PCL-5)
Time Frame: Visit 1 (Week 0)

Will be administered to subjects with history of sexual trauma.

PCL-5 is a 20-item self-reporting measure of PTSD rating how the respondent has been bothered by PTSD symptoms over the past month using a 5-point scale ranging from 0 (not at all) to 4 (extremely). Responses are summed to a total score with higher scores indicate greater PTSD symptom severity. A total symptom severity score (range 0 - 80) can be obtained by summing the scores for each of the 20 items. Research suggests that a PCL-5 cutoff score between 31-33 is indicative of probable PTSD. A 5 - 10 point change represents reliable change (i.e., change not due to chance) and a 10 - 20 point change represents clinically significant change.

Visit 1 (Week 0)
PTSD Checklist for DSM-5 (PCL-5)
Time Frame: Visit 2 (Week 4)

Will be administered to subjects with history of sexual trauma.

PCL-5 is a 20-item self-reporting measure of PTSD rating how the respondent has been bothered by PTSD symptoms over the past month using a 5-point scale ranging from 0 (not at all) to 4 (extremely). Responses are summed to a total score with higher scores indicate greater PTSD symptom severity. A total symptom severity score (range 0 - 80) can be obtained by summing the scores for each of the 20 items. Research suggests that a PCL-5 cutoff score between 31-33 is indicative of probable PTSD. A 5 - 10 point change represents reliable change (i.e., change not due to chance) and a 10 - 20 point change represents clinically significant change.

Visit 2 (Week 4)
PTSD Checklist for DSM-5 (PCL-5)
Time Frame: Visit 3 (Week 5)

Will be administered to subjects with history of sexual trauma.

PCL-5 is a 20-item self-reporting measure of PTSD rating how the respondent has been bothered by PTSD symptoms over the past month using a 5-point scale ranging from 0 (not at all) to 4 (extremely). Responses are summed to a total score with higher scores indicate greater PTSD symptom severity. A total symptom severity score (range 0 - 80) can be obtained by summing the scores for each of the 20 items. Research suggests that a PCL-5 cutoff score between 31-33 is indicative of probable PTSD. A 5 - 10 point change represents reliable change (i.e., change not due to chance) and a 10 - 20 point change represents clinically significant change.

Visit 3 (Week 5)
PTSD Checklist for DSM-5 (PCL-5)
Time Frame: Visit 4 (Week 6)

Will be administered to subjects with history of sexual trauma.

PCL-5 is a 20-item self-reporting measure of PTSD rating how the respondent has been bothered by PTSD symptoms over the past month using a 5-point scale ranging from 0 (not at all) to 4 (extremely). Responses are summed to a total score with higher scores indicate greater PTSD symptom severity. A total symptom severity score (range 0 - 80) can be obtained by summing the scores for each of the 20 items. Research suggests that a PCL-5 cutoff score between 31-33 is indicative of probable PTSD. A 5 - 10 point change represents reliable change (i.e., change not due to chance) and a 10 - 20 point change represents clinically significant change.

Visit 4 (Week 6)
PTSD Checklist for DSM-5 (PCL-5)
Time Frame: Visit 5 (Week 7)

Will be administered to subjects with history of sexual trauma.

PCL-5 is a 20-item self-reporting measure of PTSD rating how the respondent has been bothered by PTSD symptoms over the past month using a 5-point scale ranging from 0 (not at all) to 4 (extremely). Responses are summed to a total score with higher scores indicate greater PTSD symptom severity. A total symptom severity score (range 0 - 80) can be obtained by summing the scores for each of the 20 items. Research suggests that a PCL-5 cutoff score between 31-33 is indicative of probable PTSD. A 5 - 10 point change represents reliable change (i.e., change not due to chance) and a 10 - 20 point change represents clinically significant change.

Visit 5 (Week 7)
PTSD Checklist for DSM-5 (PCL-5)
Time Frame: Visit 6 (Week 11)

Will be administered to subjects with history of sexual trauma.

PCL-5 is a 20-item self-reporting measure of PTSD rating how the respondent has been bothered by PTSD symptoms over the past month using a 5-point scale ranging from 0 (not at all) to 4 (extremely). Responses are summed to a total score with higher scores indicate greater PTSD symptom severity. A total symptom severity score (range 0 - 80) can be obtained by summing the scores for each of the 20 items. Research suggests that a PCL-5 cutoff score between 31-33 is indicative of probable PTSD. A 5 - 10 point change represents reliable change (i.e., change not due to chance) and a 10 - 20 point change represents clinically significant change.

Visit 6 (Week 11)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2024

Primary Completion (Estimated)

October 1, 2026

Study Completion (Estimated)

October 1, 2026

Study Registration Dates

First Submitted

April 24, 2024

First Submitted That Met QC Criteria

April 24, 2024

First Posted (Actual)

April 29, 2024

Study Record Updates

Last Update Posted (Actual)

April 14, 2026

Last Update Submitted That Met QC Criteria

April 9, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

We do not plan on sharing data

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pelvic Pain

Clinical Trials on Standard of Care

Subscribe